A Phase 1 interventional study of JNJ-64619178 in Neoplasms, Solid Tumor, Adult and Non-Hodgkin Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 18 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson — 2 open to participants now, 7 under way, none of them phase 3. Lymphoma, Non-Hodgkin · Johnson & Johnson.
Among the 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson, this one is the 7th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2018, is one of 13 in phase 1, and was the 5th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →2 of the 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Australia, Belgium, France and 2 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Australia, Belgium, Denmark and 12 more countries
Ages 18+
By country, each count listing its studies:
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 1 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 85 across the 15 interventional studies, 2,729 across the 2 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
1 of the studies in Lymphoma, Non-Hodgkin by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06470438Janssen Research & Development, LLCA Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | 2027-10-29 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Lymphoma, Non-Hodgkin by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to identify the maximum tolerated dose (MTD) of JNJ-64619178 in participants with relapsed/refractory B cell non-Hodgkin lymphoma (NHL) or advanced solid tumors and also to identify the recommended Phase 2 dose(s) (RP2Ds) of JNJ-64619178 for NHL and advanced solid tumors (Part 1) and to confirm the tolerability of JNJ-64619178 in participants with lower risk myelodysplastic syndromes (MDS) (Part 2).
The study is designed to determine the maximum tolerated dose (MTD) of JNJ-64619178, and to select a dose(s) and regimen(s) that may be used in future clinical development. Study evaluations will include safety, pharmacokinetics, biomarkers and efficacy evaluations (Disease Assessments). Adverse events will be evaluated throughout the study. The study is divided into 4 periods: a screening phase, a pharmacokinetic run-in phase, a treatment phase, and a post treatment follow-up phase. An end-of-treatment visit will be completed less than or equal (\<=) 30 days (+7 days) after the last dose of study drug or prior to the start of a new anticancer therapy, whichever comes first.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
This study's enrollment of 114 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Browse Lymphoma, Non-Hodgkin studies →Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with solid tumors or non-Hodgkin lymphoma (NHL) will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity. One or more recommended Phase 2 dose(s) (RP2Ds) may be determined for further exploration.
Drug: JNJ-64619178
Participants with myelodysplastic syndromes (MDS) will receive JNJ-64619178 at a dose less than or equal to the RP2D selected in Part 1 for 24 weeks, or longer if there is evidence of clinical benefit. The dose level of JNJ-64619178 may be adjusted based on observed toxicities.
Drug: JNJ-64619178
JNJ-64619178 capsules to be administered orally.
Part 1 and Part 2: Number of Participants with Dose-limiting Toxicities (DLTs)
DLTs are defined as certain non-hematologic and hematologic toxicities of Grade 3 or higher.
Time frame: Approximately 3 years
Part 1 and Part 2: Number of Participants with Adverse Events (AE)
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.
Time frame: Approximately 3 years
Part 1 and Part 2: Number of Participants with AE by Severity
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Severity scale ranges from Grade 1 (Mild) to Grade 4 (Life-threatening). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.
Time frame: Approximately 3 years
Part 1 and Part 2: Number of Participants with Abnormal Vital Signs
Number of participants with abnormality in vital signs (temperature, pulse/heart rate, and blood pressure) will be reported.
Time frame: Approximately 3 years
Part 1 and Part 2: Number of Participants with Laboratory Abnormalities
Number of participants with laboratory abnormalities (serum chemistry, hematology, and coagulation, and disease-related laboratory abnormalities) will be reported.
Time frame: Approximately 3 years
Part 1 and Part 2: Number of Participants with Electrocardiogram (ECG) Abnormalities
Number of participants with electrocardiogram(ECG) abnormalities will be reported.
Time frame: Approximately 3 years
Part 1 and Part 2: Maximum Plasma Concentration (Cmax) of JNJ-64619178
Cmax is the maximum observed plasma concentration.
Time frame: Approximately 3 years
Part 1 and Part 2: Area Under the Plasma Concentration Versus Time Curve From Time Zero to End of Dosing Interval (AUCtau)
AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval.
Time frame: Approximately 3 years
Part 1 and Part 2: Minimum Plasma Concentration (Cmin)
Cmin is the minimum observed plasma concentration.
Time frame: Approximately 3 years
Part 1 and Part 2: Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Approximately 3 years
Part 1 and Part 2: Volume of Distribution at Steady-State Influenced by the Fraction Absorbed (Vss/F)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady state which is estimated by (D/AUC\[0-infinity\])\* (AUMC\[0-infinity\])/(AUC\[0-infinity\]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time. All these parameters will be assessed as influenced by the fraction absorbed.
Time frame: Approximately 3 years
Part 1 and Part 2: Apparent Total Systemic Clearance of Drug (CL/F) after Extravascular Administration
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Approximately 3 years
Part 1 and Part 2: Accumulation Index (RA)
Accumulation Index (RA) is calculated as AUC (0-24) value at steady state divided by AUC (0-24) value after first dose.
Time frame: Approximately 3 years
Part 1 and Part 2: Plasma Concentration of Symmetric Dimethyl-Arginine (SDMA)
Plasma concentration of symmetric dimethyl-arginine (SDMA) will be evaluated.
Time frame: Approximately 3 years
Part 1: Percentage of Participants with B cell non-Hodgkin lymphoma (NHL) Showing Overall Response of Partial Response (PR) or Better
Overall response rate (ORR) is defined as the percentage of participants who have a PR or better. Per Lugano classification, PR is defined as greater than or equal (\>=) 50 percent (%) decrease in size of target lesions.
Time frame: Approximately 3 years
Part 1: Percentage of Participants with Solid Tumors Showing Overall Response of PR or Better
Overall response rate (ORR) is defined as the percentage of participants who have a PR or better. PR criteria in solid tumors (RECIST) is \>= 30 percent (%) decrease in the sum of the diameters of all index lesions compared with baseline in 2 observations at least 4 weeks apart, in absence of new lesions or unequivocal progression of non-index lesions.
Time frame: Approximately 3 years
Part 1: Duration of Response
Duration of response (DOR) will be calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease (PD), as defined in the disease-specific response criteria, or death due to any cause, whichever occurs first. PD (per RECIST 1.1) defined as at least 20% increase in the sum of the longest diameters of index lesions or unequivocal progression of non-index lesions. Per Lugano classification, PD: target lesions larger; clear progression of non-target lesions; or new tumor lesions; new or recurrent bone marrow involvement; splenomegaly + 2 centimeter (cm) or +50%.
Time frame: Approximately 3 years
Part 1: Clinical Benefit Rate
Clinical benefit rate is defined as percentage of participants who have a complete response (CR), PR and sustained stable disease of 12 weeks or more. Sustained stable disease of 12 weeks or more is defined as participants with stable disease assessment maintained for about 12 weeks or longer from baseline. Per Lugano classification CR is defined as no detectable disease by computed tomography (CT) or positron emission tomography (PET)/CT scan. Evaluation criteria as per RECIST 1.1 for CR is defined as disappearance of all lesions in 2 consecutive observations not less than 4 weeks apart.
Time frame: Approximately 3 years
Part 2: Red Blood Cell (RBC) Transfusion Independence (TI) Rate
Percentage of participants with TI, defined as being without any transfusion during any consecutive 8 weeks (56 days) between the first dose of study drug and treatment discontinuation.
Time frame: Approximately 3 years
Part 2: Overall Improvement Rate
Overall improvement rate is defined as the percentage of participants achieving complete remission (bone marrow: less than or equal to (\<=)5% myeloblasts with normal maturation of all cell lines; Peripheral blood: hemoglobin \>=11 gram per deciliter (g/dL); platelets \>=100\*109/liter(L); neutrophils \>=1.0\*109/L; blasts, 0%), partial remission (All complete remission criteria if abnormal before treatment except: Bone marrow blasts decreased by \>=50% over pretreatment but still \>5% Cellularity and morphology not relevant), or hematologic improvement (HI) (Erythroid response \[pretreatment, \<11 g/dL\]; Platelet response (pretreatment, \<100\*10\^9/L); Neutrophil response (pretreatment, \<1\*10\^9/L); Progression or relapse after HI) according to modified International Working Group (IWG) criteria.
Time frame: Approximately 3 years
Ran from Jul 2018 to primary completion in Sep 2025, 86 months.
Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 86 months is above that.
Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Research & Development, LLC →